In addition, recent high-throughput sequencing studies have shown that de novo IDH1/2+ NK-AML frequently coexist with adverse risk-associated mutations in DNMT3A, ASXL1, RUNX1, SRSF2, PHF638,42–44. This evidence concerns the gene DNMT3A and acute myeloid leukemia.